Log In
BCIQ
Print this Print this
 

vibegron (KRP-114V, MK-4618)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionAdrenergic receptor beta 3 (ADRB3) agonist
Molecular Target Adrenergic receptor beta 3 (ADRB3)
Mechanism of ActionAdrenergic receptor beta 3 (ADRB3) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationIncontinence
Indication DetailsTreat overactive bladder (OAB)
Regulatory Designation
PartnerKyorin Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/30/2016

Undisclosed

0

0

07/22/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today